Martin Orrell1, Elisa Aguirre1, Aimee Spector1, Zoe Hoare1, Robert T Woods1, Amy Streater1, Helen Donovan1, Juanita Hoe1, Martin Knapp1, Christopher Whitaker1, Ian Russell1. 1. Martin Orrell, PhD, Elisa Aguirre, PhD, Unit of Mental Health Sciences, University College London, and Research and Development Department, North East London Foundation Trust, Goodmayes Hospital, Ilford; Aimee Spector, PhD, Research and Development Department, North East London Foundation Trust, Goodmayes Hospital, Ilford, and Research Department of Clinical, Educational and Health Psychology, University College London; Zoe Hoare, PhD, North Wales Organisation for Randomised Trials in Health (NWORTH), Institute of Medical & Social Care Research, Bangor; Robert T. Woods, MSc, DSDC Wales, Bangor University, Bangor; Amy Streater, MSc, Unit of Mental Health Sciences, University College London, and Research and Development Department, North East London Foundation Trust, Goodmayes Hospital, Ilford; Helen Donovan, PsyD, Clinical Psychology Service, South Essex Partnership NHS Foundation Trust, Bedford; Juanita Hoe, PhD, Unit of Mental Health Sciences, University College London, and Research and Development Department, North East London Foundation Trust, Goodmayes Hospital, Ilford; Martin Knapp, PhD, Personal Social Services Research Unit, London School of Economics and Political Science; Christopher Whitaker, MSc, North Wales Organisation for Randomised Trials in Health (NWORTH), Institute of Medical & Social Care Research, Bangor; Ian Russell, PhD, Swansea University, College of Medicine, Singleton Park, Swansea, UK.
Abstract
BACKGROUND: There is good evidence for the benefits of short-term cognitive stimulation therapy for dementia but little is known about possible long-term effects. AIMS: To evaluate the effectiveness of maintenance cognitive stimulation therapy (CST) for people with dementia in a single-blind, pragmatic randomised controlled trial including a substudy with participants taking acetylcholinesterase inhibitors (AChEIs). METHOD: The participants were 236 people with dementia from 9 care homes and 9 community services. Prior to randomisation all participants received the 7-week, 14-session CST programme. The intervention group received the weekly maintenance CST group programme for 24 weeks. The control group received usual care. Primary outcomes were cognition and quality of life (clinical trial registration: ISRCTN26286067). RESULTS: For the intervention group at the 6-month primary end-point there were significant benefits for self-rated quality of life (Quality of Life in Alzheimer's Disease (QoL-AD) P = 0.03). At 3 months there were improvements for proxy-rated quality of life (QoL-AD P = 0.01, Dementia Quality of Life scale (DEMQOL) P = 0.03) and activities of daily living (P = 0.04). The intervention subgroup taking AChEIs showed cognitive benefits (on the Mini-Mental State Examination) at 3 (P = 0.03) and 6 months (P = 0.03). CONCLUSIONS: Continuing CST improves quality of life; and improves cognition for those taking AChEIs. Royal College of Psychiatrists.
RCT Entities:
BACKGROUND: There is good evidence for the benefits of short-term cognitive stimulation therapy for dementia but little is known about possible long-term effects. AIMS: To evaluate the effectiveness of maintenance cognitive stimulation therapy (CST) for people with dementia in a single-blind, pragmatic randomised controlled trial including a substudy with participants taking acetylcholinesterase inhibitors (AChEIs). METHOD: The participants were 236 people with dementia from 9 care homes and 9 community services. Prior to randomisation all participants received the 7-week, 14-session CST programme. The intervention group received the weekly maintenance CST group programme for 24 weeks. The control group received usual care. Primary outcomes were cognition and quality of life (clinical trial registration: ISRCTN26286067). RESULTS: For the intervention group at the 6-month primary end-point there were significant benefits for self-rated quality of life (Quality of Life in Alzheimer's Disease (QoL-AD) P = 0.03). At 3 months there were improvements for proxy-rated quality of life (QoL-AD P = 0.01, Dementia Quality of Life scale (DEMQOL) P = 0.03) and activities of daily living (P = 0.04). The intervention subgroup taking AChEIs showed cognitive benefits (on the Mini-Mental State Examination) at 3 (P = 0.03) and 6 months (P = 0.03). CONCLUSIONS: Continuing CST improves quality of life; and improves cognition for those taking AChEIs. Royal College of Psychiatrists.
Authors: Martin Knapp; Kia-Chong Chua; Matthew Broadbent; Chin-Kuo Chang; Jose-Luis Fernandez; Dominique Milea; Renee Romeo; Simon Lovestone; Michael Spencer; Gwilym Thompson; Robert Stewart; Richard D Hayes Journal: BMJ Open Date: 2016-11-18 Impact factor: 2.692
Authors: Martin Orrell; Lauren Yates; Phuong Leung; Sujin Kang; Zoe Hoare; Chris Whitaker; Alistair Burns; Martin Knapp; Iracema Leroi; Esme Moniz-Cook; Stephen Pearson; Stephen Simpson; Aimee Spector; Steven Roberts; Ian Russell; Hugo de Waal; Robert T Woods; Vasiliki Orgeta Journal: PLoS Med Date: 2017-03-28 Impact factor: 11.069
Authors: Adelina Comas-Herrera; Martin Knapp; Raphael Wittenberg; Sube Banerjee; Ann Bowling; Emily Grundy; Carol Jagger; Nicolas Farina; Daniel Lombard; Klara Lorenz; David McDaid Journal: BMC Health Serv Res Date: 2017-01-11 Impact factor: 2.655
Authors: Robert T Woods; Martin Orrell; Errollyn Bruce; Rhiannon T Edwards; Zoe Hoare; Barry Hounsome; John Keady; Esme Moniz-Cook; Vasiliki Orgeta; Janice Rees; Ian Russell Journal: PLoS One Date: 2016-04-19 Impact factor: 3.240